{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T04:13:11Z","timestamp":1648786391282},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[1997,4,1]],"date-time":"1997-04-01T00:00:00Z","timestamp":859852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[1997,4]]},"DOI":"10.1006\/gyno.1997.4622","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T22:50:18Z","timestamp":1032303018000},"page":"42-45","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Study of 96-hr Continuous-Infusion Etoposide and Doxorubicin with Bolus Cyclophosphamide in Refractory Epithelial Ovarian Cancer"],"prefix":"10.1006","volume":"65","author":[{"given":"Gini F.","family":"Fleming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Rotmensch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda A.","family":"Skoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Langhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.1997.4622_GO974622C1","first-page":"222","article-title":"Chemotherapy of ovarian cancer","volume":"18","author":"Ozols","year":"1991","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C2","doi-asserted-by":"crossref","unstructured":"J, T, Thigpen, Chemotherapy in the Management of Celomic Epithelial Carcinoma of the Ovary, Cancer of the Ovary, 277, 286, Raven Press, New York","DOI":"10.3109\/07357909709039727"},{"key":"10.1006\/gyno.1997.4622_GO974622C3","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","article-title":"Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103","volume":"11","author":"Trimble","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1006\/gyno.1997.4622_GO974622C5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1006\/gyno.1997.4622_GO974622C7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","article-title":"Oral etoposide is active against platinum-resistant epithelial ovarian cancer","volume":"12","author":"Hoskins","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C8","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C9","first-page":"264","article-title":"Multi-agent constant infusion chemotherapy in gynecologic oncology patients","volume":"13","author":"Semrad","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C10","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C11","series-title":"Cancer Chemotherapy by Infusion","first-page":"368","article-title":"Gynecologic Malignancy","author":"Muss","year":"1987"},{"key":"10.1006\/gyno.1997.4622_GO974622C12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ijc.2910490512","article-title":"P-Glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines","volume":"49","author":"Lai","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1006\/gyno.1997.4622_GO974622C13","first-page":"1355","article-title":"Expression of the multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer","volume":"54","author":"Arao","year":"1994","journal-title":"Cancer Res"},{"key":"10.1006\/gyno.1997.4622_GO974622C14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1995.13.1.70","article-title":"Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas","volume":"13","author":"Van der Zee","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C15","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/jnci\/87.16.1230","article-title":"Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma","volume":"87","author":"Izquierdo","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.1997.4622_GO974622C16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.1995.1205","article-title":"Cell biological markers of drug resistance in ovarian carcinoma","volume":"58","author":"van der Zee","year":"1995","journal-title":"Gyn Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C17","series-title":"Cancer Principles and Practice of Oncology","first-page":"2385","article-title":"Oral Complications of Cancer Therapy","author":"Sonis","year":"1993"},{"key":"10.1006\/gyno.1997.4622_GO974622C18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1259\/0007-1285-63-751-554","article-title":"Smoking and mucosal reactions to radiotherapy","volume":"63","author":"Rugg","year":"1990","journal-title":"Br J Radiat"},{"key":"10.1006\/gyno.1997.4622_GO974622C19","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","article-title":"European\u2013Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion","volume":"12","author":"Eisenhauer","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/gyno.1994.1144","article-title":"Exponential regression of CA 125 during salvage treatment of cancer with taxol","volume":"53","author":"Pearl","year":"1994","journal-title":"Gyn Oncol"},{"key":"10.1006\/gyno.1997.4622_GO974622C21","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/annonc\/4.suppl_4.S71","article-title":"Tumour markers","volume":"4","author":"Rustin","year":"1993","journal-title":"Ann Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825897946229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825897946229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T20:08:50Z","timestamp":1576526930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825897946229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,4]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,4]]}},"alternative-id":["S0090825897946229"],"URL":"https:\/\/doi.org\/10.1006\/gyno.1997.4622","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[1997,4]]}}}